{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-021986","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.472366+00:00","generated_at":"2026-05-25T00:59:18.403419+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Icotrokinra Phase 3 PsO hits 46% complete skin clearance; UC Phase 2b meets endpoint","bullets":["Phase 3 ICONIC-LEAD: 46% of icotrokinra patients achieved IGA 0 (completely clear skin) at Week 24; 74% IGA 0/1.","ICONIC-ADVANCE 1&2 met co-primary endpoints and showed superiority over deucravacitinib at Weeks 16 and 24; head-to-head vs ustekinumab (ICONIC-ASCEND) initiated.","Phase 2b ANTHEM-UC: 63.5% clinical response at highest dose at Week 12 vs 27.0% placebo (p<0.001); 30.2% clinical remission vs 11.1% (p<0.001).","Both studies show favorable safety; AEs similar to placebo. Icotrokinra is a first-in-class oral IL-23 receptor antagonist.","Results support potential paradigm shift in plaque psoriasis and ulcerative colitis; partner J&J advancing program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-021986","json":"https://secwatch.observer/filing/0001104659-25-021986.json","markdown":"https://secwatch.observer/filing/0001104659-25-021986.md","text":"https://secwatch.observer/filing/0001104659-25-021986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/0001104659-25-021986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/tm258665d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:59:18.403419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}